Author
Rodrigo Isa
Bio: Rodrigo Isa is an academic researcher. The author has contributed to research in topics: Risk assessment & Risk management tools. The author has an hindex of 1, co-authored 1 publications receiving 32 citations.
Topics: Risk assessment, Risk management tools, Population
Papers
More filters
Aarhus University Hospital1, Taipei Veterans General Hospital2, State University of Campinas3, Leipzig University4, Argerich Hospital5, University of Wisconsin-Madison6, Virginia Commonwealth University7, University of São Paulo8, Toho University9, Case Western Reserve University10, University of British Columbia11, University of Rochester Medical Center12, Semmelweis University13, University of Melbourne14, Aalborg University15, University of Liverpool16, University Health System17, Institute for Social Security and Services for State Workers18, Brigham and Women's Hospital19, University of Copenhagen20, University of California, Los Angeles21, University of Amsterdam22, Intermountain Medical Center23, Beth Israel Deaconess Medical Center24, Ludwig Maximilian University of Munich25, Libin Cardiovascular Institute of Alberta26, University of California, San Francisco27, University of Ulsan28, Roy J. and Lucille A. Carver College of Medicine29, Sree Chitra Thirunal Institute for Medical Sciences and Technology30, Anschutz Medical Campus31, Ruhr University Bochum32, Waikato Hospital33, McGill University34, University of Rennes35
TL;DR: This expert consensus statement task force was set down to raise awareness of using the right risk assessment tool for a given outcome in a given population, and to provide physicians with practical proposals that may lead to rational and evidence-based risk assessment and improvement of patient care in this regard.
62 citations
Cited by
More filters
01 Jan 2019
TL;DR: In this paper, Brignole, Moya, and van Dijk proposed a task force for gender equality in the workplace, with the task force's chairperson Michele Bignole and co-chairmen Angel Moya and Jean-Claude Deharo.
Abstract: Authors/Task Force Members: Michele Brignole* (Chairperson) (Italy), Angel Moya* (Co-chairperson) (Spain), Frederik J. de Lange (The Netherlands), Jean-Claude Deharo (France), Perry M. Elliott (UK), Alessandra Fanciulli (Austria), Artur Fedorowski (Sweden), Raffaello Furlan (Italy), Rose Anne Kenny (Ireland), Alfonso Mart ın (Spain), Vincent Probst (France), Matthew J. Reed (UK), Ciara P. Rice (Ireland), Richard Sutton (Monaco), Andrea Ungar (Italy), and J. Gert van Dijk (The Netherlands)
292 citations
Case Western Reserve University1, Duke University2, Harvard University3, Johns Hopkins University4, Boston University5, University of Groningen6, Indiana University7, University of California, Davis8, Vanderbilt University9, University of Wisconsin-Madison10, University of Calgary11, McMaster University12, Goethe University Frankfurt13, Cornell University14, National Institutes of Health15, Aalborg University16, University of Birmingham17, Cleveland Clinic Lerner College of Medicine18, Stanford University19, University of California, San Francisco20, Mayo Clinic21, National Health Service22, Arizona State University23, Baylor College of Medicine24
TL;DR: The Heart Rhythm Society convened a research symposium on December 9-10, 2013, in Washington, DC, that focused on the prevention of atrial fibrillation (AF) as well as AF-related stroke and morbidity as discussed by the authors.
Abstract: The Heart Rhythm Society convened a research symposium on December 9–10, 2013, in Washington, DC, that focused on the prevention of atrial fibrillation (AF) as well as AF-related stroke and morbidity. Attendees sought to summarize advances in understanding AF since a 2008 National Institutes of Health (NIH) conference on this topic1 and to identify continued knowledge gaps and current research priorities. The research symposium also sought to identify key deficiencies and opportunities in research infrastructure, operations, and methodologies. The committee sought to identify both basic research targets and how clinical AF research could be improved in the current health care environment. This whitepaper summarizes our deliberations in an effort to accelerate progress toward preventing AF and its consequences. Although largely focused on primary prevention of AF, the paper also addresses some aspects of secondary prevention of recurrent AF due to the continuum of risk factors that contribute to arrhythmogenesis, permissive left atrial (LA) substrates, and the emergence of AF.
79 citations
TL;DR: The results of this study suggested that the examined smartwatch (Apple Watch Series 4) could obtain 3-lead ECG tracings, including Einthoven leads I, II, and III by placing the smartwatch on the described positions.
Abstract: Some of the recently released smartwatch products feature a single-lead electrocardiogram (ECG) recording capability. The reliability of obtaining 3-lead ECG with smartwatches is yet to be confirmed in a large study. This study aimed to assess the feasibility and reliability of smartwatch to obtain 3-lead ECG recordings, the classical Einthoven ECG leads I-III compared to standard ECG. To record lead I, the watch was worn on the left wrist and the right index finger was placed on the digital crown for 30 s. For lead II, the watch was placed on the lower abdomen and the right index finger was placed on the digital crown for 30 s. For lead III, the same process was repeated with the left index finger. Spearman correlation and Bland-Altman tests were used for data analysis. A total of 300 smartwatch ECG tracings were successfully obtained. ECG waves' characteristics of all three leads obtained from the smartwatch had a similar duration, amplitude, and polarity compared to standard ECG. The results of this study suggested that the examined smartwatch (Apple Watch Series 4) could obtain 3-lead ECG tracings, including Einthoven leads I, II, and III by placing the smartwatch on the described positions.
33 citations
University of Sydney1, University College London2, Queen's University3, Capital Medical University4, Queen's University Belfast5, McMaster University6, Toho University7, Atrial Fibrillation Association8, Lagos University Teaching Hospital9, Edinburgh Napier University10, Mayo Clinic11, Brown University12, University of Copenhagen13, University of Barcelona14, University of Oxford15, Autonomous University of Barcelona16, All India Institute of Medical Sciences17, University of Adelaide18, World Heart Federation19, University of Buenos Aires20, Universidade Federal de Minas Gerais21
TL;DR: The World Heart Federation (WHF) initiated a Roadmap initiative in 2015 to reduce the global burden of cardiovascular disease and resultant burgeoning of healthcare costs as mentioned in this paper, where the goal was to provide guidance on priority interventions that are feasible in multiple countries, and to identify roadblocks and potential strategies to overcome them.
Abstract: The World Heart Federation (WHF) commenced a Roadmap initiative in 2015 to reduce the global burden of cardiovascular disease and resultant burgeoning of healthcare costs. Roadmaps provide a blueprint for implementation of priority solutions for the principal cardiovascular diseases leading to death and disability. Atrial fibrillation (AF) is one of these conditions and is an increasing problem due to ageing of the world's population and an increase in cardiovascular risk factors that predispose to AF. The goal of the AF roadmap was to provide guidance on priority interventions that are feasible in multiple countries, and to identify roadblocks and potential strategies to overcome them. Since publication of the AF Roadmap in 2017, there have been many technological advances including devices and artificial intelligence for identification and prediction of unknown AF, better methods to achieve rhythm control, and widespread uptake of smartphones and apps that could facilitate new approaches to healthcare delivery and increasing community AF awareness. In addition, the World Health Organisation added the non-vitamin K antagonist oral anticoagulants (NOACs) to the Essential Medicines List, making it possible to increase advocacy for their widespread adoption as therapy to prevent stroke. These advances motivated the WHF to commission a 2020 AF Roadmap update. Three years after the original Roadmap publication, the identified barriers and solutions were judged still relevant, and progress has been slow. This 2020 Roadmap update reviews the significant changes since 2017 and identifies priority areas for achieving the goals of reducing death and disability related to AF, particularly targeted at low-middle income countries. These include advocacy to increase appreciation of the scope of the problem; plugging gaps in guideline management and prevention through physician education, increasing patient health literacy, and novel ways to increase access to integrated healthcare including mHealth and digital transformations; and greater emphasis on achieving practical solutions to national and regional entrenched barriers. Despite the advances reviewed in this update, the task will not be easy, but the health rewards of implementing solutions that are both innovative and practical will be great.
26 citations
TL;DR: In patients without permanent AF, progression of AF was independently associated with age, LA dilation, AF symptoms severity, antiarrhythmic drugs and valvular disease, and addingLA dilation to clinical scores improved prediction of progression to permanent AF.
Abstract: Atrial fibrillation (AF) may progress from a non-permanent to a permanent form, and improvement in prediction may help in decision-making. In- and outpatients with non-permanent AF were enrolled in a prospective study and followed every 6 months. At baseline, 314 out of 523 patients (60%) had non-permanent AF (25.5% paroxysmal AF, 52.5% persistent, 2% first diagnosed AF). They were mostly males (188, 59.9%), median age 71 years [interquartile range (IQ) 62–77], median CHA2DS2VASc 3 (IQ 1–4), median HATCH score 1 (IQ 1–2). During a follow-up of 701 (IQ 437–902) days, 66 patients (21%) developed permanent AF. CHA2DS2VASc and HATCH scores were incrementally associated with AF progression (p for trend CHA2DS2VASc 2 (HR 0.358, 95%CI 0.162–0.791, p = 0.011) and valvular disease (HR 2.196, 95%CI 1.072–4.499, p = 0.032) were significantly associated with AF progression. Adding “moderate–severe LA dilation” to clinical scores, eg. HATCH score (HATCH-LA) with 2 points (Cox multivariable regression analysis) improved prediction of AF progression vs. HATCH score (p = 0.0225). In patients without permanent AF, progression of AF was independently associated with age, LA dilation, AF symptoms severity, antiarrhythmic drugs and valvular disease. Adding LA dilation (moderate–severe volume increase) to clinical scores improved prediction of progression to permanent AF.
22 citations